Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 54Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Myeloproliferative Disorders 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 16Primary Myelofibrosis 13Leukemia 11Hodgkin Disease 11Sarcoma 9Polycythemia Vera 9Neuroblastoma 9Histiocytosis, Langerhans-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Leukemia, Biphenotypic, Acute 8Hepatoblastoma 8Ependymoma 8Anemia, Refractory, with Excess of Blasts 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7Myelodysplastic-Myeloproliferative Diseases 7Blast Crisis 7Multiple Myeloma 6Blastic Plasmacytoid Dendritic Cell Neoplasm 6

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Mesothelial × Myeloid × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡